Castle Biosciences (CSTL) Expected to Release Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Castle Biosciences to announce earnings of ($0.3480) per share and revenue of $92.77 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $35.14 on Wednesday. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $34.27 and its 200-day simple moving average is $28.63. Castle Biosciences has a twelve month low of $17.72 and a twelve month high of $44.28.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research report on Friday, July 31st. Mizuho began coverage on shares of Castle Biosciences in a research note on Thursday, October 29th. They set an “outperform” rating and a $60.00 price target for the company. BTIG Research lifted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 29th. Finally, Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Transactions at Castle Biosciences

In other news, COO Kristen Oelschlager sold 12,384 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total value of $426,257.28. Following the transaction, the chief operating officer directly owned 72,649 shares of the company’s stock, valued at $2,500,578.58. The trade was a 14.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 12,428 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the sale, the insider owned 21,479 shares in the company, valued at approximately $713,102.80. This trade represents a 36.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 126,184 shares of company stock valued at $4,324,506 in the last three months. 6.10% of the stock is owned by corporate insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.